Prochlorperazine and Mirabegron drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Prochlorperazine (prochlorperazine) and Mirabegron (mirabegron). Common drug interactions include fatigue among females and capillary leak syndrome among males.

The phase IV clinical study analyzes what interactions people have when they take Prochlorperazine and Mirabegron. It is created by eHealthMe based on reports of 40 people who take the same drugs from the FDA, and is updated regularly.

What is Prochlorperazine?

Prochlorperazine has active ingredients of prochlorperazine. It is often used in nausea. eHealthMe is studying from 14,632 Prochlorperazine users. Check the latest studies of Prochlorperazine.

What is Mirabegron?

Mirabegron has active ingredients of mirabegron. It is often used in urge incontinence. eHealthMe is studying from 5,414 Mirabegron users. Check the latest studies of Mirabegron.

On Jul, 16, 2026

40 people who take Prochlorperazine and Mirabegron together, and have interactions are studied.

Prochlorperazine and Mirabegron drug interactions.

What are the common drug interactions of Prochlorperazine and Mirabegron, by gender? *:

female:

Fatigue (feeling of tiredness)
Pain in extremity
Distributive shock (hock caused by poor distribution of the blood flow)
Alanine aminotransferase increased
Aspartate aminotransferase increased
Blood alkaline phosphatase increased
Cellulitis (infection under the skin)
Enterococcus test positive
Haematocrit decreased
Haemoglobin decreased

male:

Capillary leak syndrome (capillary leaks plasma)
Diarrhoea
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood)
Pyrexia (fever)
Blood lactic acid increased
Cardiac failure
Rash
Tachycardia (a heart rate that exceeds the range of 100 beats/min)
Fall
Generalised oedema (swelling all over the body)

What are the common drug interactions of Prochlorperazine and Mirabegron, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Fatigue (feeling of tiredness)
Pain in extremity

40-49:

n/a

50-59:

n/a

60+:

Capillary leak syndrome (capillary leaks plasma)
Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood)
Staphylococcal infection (an infection with staphylococcus bacteria)
Blood lactic acid increased
Cardiac failure
Tachycardia (a heart rate that exceeds the range of 100 beats/min)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Arthralgia (joint pain)
Fall

What are the existing conditions these people have? *

Insomnia (sleeplessness): 6 people, 15.00%
Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 6 people, 15.00%
Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 5 people, 12.50%
Constipation: 5 people, 12.50%
Depression: 5 people, 12.50%
Diarrhea: 5 people, 12.50%
High Blood Cholesterol: 5 people, 12.50%
High Blood Pressure: 5 people, 12.50%
Indigestion: 5 people, 12.50%
Bladder Disorder: 5 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Prochlorperazine and Mirabegron?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously